Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer's Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab

被引：1
|
作者：
Melo, V. S. D. [1 ]
Rodrigues, C. A. [1 ]
Silva, I. A. [2 ]
机构：
[1] Ctr Hosp Medio Tejo, Psychiat, Tomar, Portugal
[2] Unidade Local Saude Norte Alentejano, Psychiat, Portalegre, Portugal
来源：
EUROPEAN PSYCHIATRY | 2023年 / 66卷
关键词：
D O I：
10.1192/j.eurpsy.2023.663
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPP0346
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [21] Immunotherapy for Parkinson's Disease and Alzheimer's Disease: A Promising Disease-Modifying Therapy
    Mahboob, Anns
    Ali, Hasan
    Alnaimi, Aljazi
    Yousef, Mahmoud
    Rob, Mlaak
    Al-Muhannadi, Nawaf Ahmad
    Senevirathne, Degiri Kalana Lasanga
    Chaari, Ali
    CELLS, 2024, 13 (18)
  • [22] The past, present, and future of disease-modifying therapies for Alzheimer's disease
    Suzuki, Kazushi
    Iwata, Atsushi
    Iwatsubo, Takeshi
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2017, 93 (10): : 757 - 771
  • [23] Challenges in demonstrating the value of disease-modifying therapies for Alzheimer's disease
    Gustavsson, Anders
    Pemberton-Ross, Peter
    Montero, Melissa Gomez
    Hashim, Mahmoud
    Thompson, Robin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (06) : 563 - 570
  • [24] Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies
    Guo, Michael H.
    Vaishnavi, Sanjeev N.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2023, 25 (05) : 121 - 133
  • [25] Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
    Michael H. Guo
    Sanjeev N. Vaishnavi
    Current Treatment Options in Neurology, 2023, 25 : 121 - 133
  • [26] Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
    Cummings J.
    Osse A.M.L.
    Cammann D.
    Powell J.
    Chen J.
    BioDrugs, 2024, 38 (1) : 5 - 22
  • [27] Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
    Linda Söderberg
    Malin Johannesson
    Patrik Nygren
    Hanna Laudon
    Fredrik Eriksson
    Gunilla Osswald
    Christer Möller
    Lars Lannfelt
    Neurotherapeutics, 2023, 20 (1) : 195 - 206
  • [28] DIAN-TU Alzheimer's Disease Prevention Trial of Solanezumab and Gantenerumab: Amyloid, Tau and Neurodegeneration Outcomes
    Bateman, Randall
    Aschenbrenner, Andrew
    Benzinger, Tammie
    Clifford, David
    Cruchaga, Carlos
    Fagan, Anne
    Farlow, Martin
    Goate, Alison
    Gordon, Brian
    Hassenstab, Jason
    Jack, Clifford
    Koeppe, Robert
    McDade, Eric
    Mills, Susan
    Morris, John C.
    Salloway, Stephen
    Santacruz, Anna
    Snyder, Peter
    Wang, Guoqiao
    Xiong, Chengjie
    Snider, Barbara J.
    Mummery, Catherine
    Surti, Ghulam
    Didier, Hannequin
    Wallon, David
    Berman, Sarah
    Lah, James
    Jimenez-Velazquez, Ivonne Z.
    Roberson, Erik
    Van Dyck, Christopher
    Honig, Lawrence S.
    Valle, Raquel Sanchez
    Brooks, William S.
    Gauthier, Serge
    Masters, Colin
    Galasko, Douglas
    Brosch, Jared
    Hsiung, Robin
    Jayadev, Suman
    Formaglio, Maite
    Masellis, Mario
    Clarnette, Roger
    Pariente, Jeremie
    Dubois, Bruno
    Pasquier, Florence
    Andersen, Scott
    Holdridge, Karen
    Mintun, Mark
    Sims, John
    Yaari, Roy
    ANNALS OF NEUROLOGY, 2020, 88 : S103 - S103
  • [29] Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease
    Soderberg, Linda
    Johannesson, Malin
    Nygren, Patrik
    Laudon, Hanna
    Eriksson, Fredrik
    Osswald, Gunilla
    Moller, Christer
    Lannfelt, Lars
    NEUROTHERAPEUTICS, 2023, 20 (01) : 195 - 206
  • [30] Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review
    Chowdhury, Selia
    Chowdhury, Nurjahan Shipa
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2023, 37
12345